Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Researchers design new model to identify promising candidates for total hip replacement surgery

Researchers at Sahlgrenska Academy have designed a new model to help doctors and patients decide whether or not to proceed with total hip replacement surgery. The researchers have also surveyed patient wellbeing after surgery: patients with high education achieve greater outcome scores, while those with antidepressant prescriptions do not.

28 May 2015

Manic symptoms during depression warn of polarity switch

Concomitant manic symptoms and panic attacks are the strongest predictors of an impending switch to mania among patients with bipolar disorder who are currently depressed, shows analysis of the STEP-BD study.

27 May 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.

22 May 2015

Magstim Announces FDA (510k) Clearance of rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System

Magstim is the pioneer of TMS technology, having built a reputation for developing leading medical devices in the research field for over 25 years. ..

From Magstim 21 May 2015

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.

From Magstim 20 May 2015

New method may help determine potential indicator of stress, neurological disorders

A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential. The new method that combines phase extraction with an enzymatic reaction may eventually be used for an improved and faster screening analysis of isatin as a potential indicator of stress and neurological disorders.

12 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder.

29 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

Mindfulness-based cognitive therapy could offer new treatment choice for people with recurrent depression

Mindfulness-based cognitive therapy (MBCT) could provide an alternative non-drug treatment for people who do not wish to continue long-term antidepressant treatment, suggests new research published in The Lancet.

22 Apr 2015

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors.

21 Apr 2015

Prenatal antidepressant exposure increases anxiety symptoms

Three-year-old siblings exposed to antidepressants in pregnancy show increased anxiety symptoms compared to their unexposed siblings.

21 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Study demonstrates effective tool for enhancing recognition of adolescent depression

Training pediatric primary care providers to screen and assess depression and suicide risk in adolescent patients improved providers' confidence and knowledge of these conditions and increased frequency of screenings for this critical patient population. The study, published in the May/June issue of Academic Pediatrics, demonstrates an effective tool for improving recognition of adolescent depression.

2 Apr 2015

Screening people at risk of PTSD can help prevent further cases going unnoticed

When people have repeated non-specific health problems, it could be related to previous exposure to traumatic events. GPs may be seeing more patients with post-traumatic stress disorder (PTSD) as military personnel return from overseas deployments.

1 Apr 2015

New analysis raises questions about common use of antidepressant drugs for anxiety disorders

A new analysis reported in JAMA Psychiatry raises serious questions about the increasingly common use of second-generation antidepressant drugs to treat anxiety disorders.

31 Mar 2015

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania.

27 Mar 2015

Early response plus genetic variants strengthen antidepressant outcome prediction

Considering genetic variants in combination with early partial improvement could be useful for predicting antidepressant outcome, say researchers.

24 Mar 2015

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain.

18 Mar 2015